February 06, 200 -Tornier, Inc., a global leader in extremities orthopedics, announced that it has entered into an exclusive world-wide technology collaboration in the field of orthopedic soft tissue repair with BioSurface Engineering Technologies, Inc. ("BioSET") to develop, commercialize, and distribute products that will incorporate BioSET’s synthetic growth factor technology. The collaboration will focus initially on ligament and tendon repair products that will feature coatings based on BioSET’s proprietary F2A synthetic growth factor technology (“F2A”)... Tornier's Press Release-
Blog Archive
-
▼
2008
(66)
-
▼
February
(13)
- Genfit and Pierre Fabre, alliance
- UCB and sanofi-aventis, FDA Approves XYZAL® (levoc...
- LFB and the French Rare Diseases Alliance, Partner...
- IPSOGEN, Genomic Grade to improve Breast Cancer di...
- Sanofi Pasteur and Statens Serum Institut , develo...
- NOVEXEL AND FOREST LABORATORIES, LICENSE AGREEMENT...
- Trophos, grant from The Michael J. Fox Foundation ...
- Servier, Medicinal Chemistry Research Center in Bu...
- Faust Pharmaceuticals, Research Agreement with Takeda
- Tornier and Bioset Collaborate on Products for Ort...
- Novagali Pharma, FDA Clearance of IND for US Clini...
- Ipsen, a Biologics License Application (BLA) for D...
- Cerep, to provide profiling services to support a ...
-
▼
February
(13)